We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several pharmacologic properties that make it unique among taxanes, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life ("t1/2") in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. More than 500 patients have been treated with tesetaxel in clinical studies. In patients with metastatic breast cancer (âMBCâ), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. In December 2017, Odonate initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer ("LA/MBC") (clinicaltrials.gov). Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. Source
No articles found.
Global Cancer Technology was formed to acquire a portfolio of various medical lice...
Global Cancer Technology was formed to acquire ...
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and a...
CASI is a U.S. NASDAQ-listed biopharmaceutical ...
We are a fully integrated biopharmaceutical company focused on the development and...
We are a fully integrated biopharmaceutical com...
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company based in T...
China SXT Pharmaceuticals, Inc. is an innovativ...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Join the National Investor Network and get the latest information with your interests in mind.